靶向CD47在膀胱癌治疗中的研究进展  

Research progress of targeted CD47 in the treatment of bladder cancer

作　　者：秦华阳 王梦飞 王钰雄 王远涛[1] Qin Huayang;Wang Mengfei;Wang Yuxiong;Wang Yuantao(The Second Department of Urology,The First Bethune Hospital of Jilin University,Changchun 130021,China)

机构地区：[1]吉林大学白求恩第一医院泌尿外二科,长春130021

出　　处：《中华泌尿外科杂志》2023年第5期398-400,共3页Chinese Journal of Urology

摘　　要：CD47是广泛表达的跨膜糖蛋白,是肿瘤细胞发生免疫逃逸的重要信号分子。膀胱癌细胞高表达的CD47分子,可与巨噬细胞表面的信号调节蛋白α(SIRPα)结合并传递免疫抑制性信号,保护肿瘤细胞免受吞噬,从而介导其发生免疫逃逸。CD47-SIRPα信号通路已成为现阶段肿瘤细胞免疫检查点研究的热点。通过应用靶向CD47的纳米技术、化疗药物、近红外光疗法,在膀胱癌的诊断、治疗及预后判断方面取得了较好的效果。本文就CD47在膀胱癌中的作用机制和临床应用价值等方面的研究进展进行综述。CD47 is a transmembrane glycoprotein widely expressed on cells and an important signal molecule for immune escape of tumor cells.CD47,which is highly expressed in bladder cancer cells,can interact with signal regulatory proteins on the surface of macrophages-α(SIRPα).It combines and transmits immunosuppressive signals to protect tumor cells from phagocytosis,thereby mediating their immune escape.CD47-SIRPαsignal pathways have become the focus of tumor cell immune checkpoint research at this stage.This article reviewed the research progress in the mechanism and clinical value of CD47 in bladder cancer.

关 键 词：膀胱肿瘤 癌 整合素相关蛋白 靶向治疗 

分 类 号：R737.14[医药卫生—肿瘤]